SUPRAME-ACTengine IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

• Status: RECRUITING
• Trial end date: 2031-10-01

Summary

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.

• Phase: PHASE3

Details

• Lead Sponsor: Immatics US, Inc.
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Dacarbazine; Ipilimumab; lifileucel; Nivolumab; Opdualag; Paclitaxel; pembrolizumab; relatlimab; Temozolomide